RT Journal Article
SR Electronic
T1 Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement
JF British Journal of Ophthalmology
JO Br J Ophthalmol
FD BMJ Publishing Group Ltd.
SP 1023
OP 1027
DO 10.1136/bjophthalmol-2013-304453
VO 98
IS 8
A1 Atsuki Fukushima
A1 Yuichi Ohashi
A1 Nobuyuki Ebihara
A1 Eiichi Uchio
A1 Shigeki Okamoto
A1 Naoki Kumagai
A1 Jun Shoji
A1 Etsuko Takamura
A1 Yayoi Nakagawa
A1 Kenichi Namba
A1 Hiroshi Fujishima
A1 Dai Miyazaki
YR 2014
UL http://bjo.bmj.com/content/98/8/1023.abstract
AB Background The objective of this study was to investigate the efficacy of topical 0.1% tacrolimus in treating refractory allergic conjunctivitis with proliferative lesions and/or corneal involvement. Methods This prospective observational study included 1436 patients with refractory allergic conjunctivitis whose condition had responded poorly to conventional antiallergic drugs and/or topical steroids and/or topical cyclosporine. All patients received tacrolimus eye drops twice daily during the study period. Ten clinical signs and six clinical symptoms were rated on a four-grade scale. The primary endpoint was the change from baseline in total clinical signs and symptoms score at the last observation or following 6 months of treatment. Results Total signs and symptoms score significantly decreased after 1 month of treatment (p<0.001). Giant papillae and corneal lesions were also reduced by tacrolimus eye drop use (p<0.001). The drug proved effective in patients whose condition did not respond well to topical cyclosporine therapy. About 50% of all patients using topical steroids were weaned. The most common adverse reaction was a transient burning sensation (3.20%). Conclusions Tacrolimus eye drops are highly effective in treating refractory allergic conjunctivitis with proliferative lesions and/or corneal involvement, and may reduce or replace topical steroid use. Trial registration number UMIN 000008640.